MARKET

AGRX

AGRX

Agile
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.428
+0.053
+2.22%
Opening 15:01 07/14 EDT
OPEN
2.390
PREV CLOSE
2.375
HIGH
2.450
LOW
2.320
VOLUME
797.94K
TURNOVER
--
52 WEEK HIGH
4.765
52 WEEK LOW
0.3500
MARKET CAP
211.74M
P/E (TTM)
-6.7271
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AGRX stock price target is 7.50 with a high estimate of 8.00 and a low estimate of 6.00.

EPS

AGRX News

More
Hedge Funds Have Never Been This Bullish On Agile Therapeutics Inc (AGRX)
Insider Monkey · 07/01 06:22
Agile Therapeutics On June 26 Established A Wholesale Acquisition Cost Of $159.75 For A Treatment Cycle Of Its Twirla Transdermal System; Each Twirla Treatment Cycle Is Packaged In A Carton Containing 3 Individually Pouched Transdermal Systems
On June 26, 2020, Agile Therapeutics, Inc. established a wholesale acquisition cost of $159.75 for a treatment cycle of its TWIRLA® (levonorgestrel and ethinyl estradiol) transdermal system.  Each TWIRLA
Benzinga · 06/30 10:37
How Agile Therapeutics (AGRX) Stock Stands Out in a Strong Industry
Zacks · 06/23 13:30
BioMarin's Hemophilia Data, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 06/19 14:46
Agile Therapeutics to Join Russell 3000® and 2000® Indexes
GlobeNewswire · 06/16 13:00
Agile Therapeutics To Join Russell 3000 And 2000 Indexes
PRINCETON, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women’s healthcare company, today announced that the Company will be added to the Russell 3000® and 2000®
Benzinga · 06/16 12:16
Billionaire Israel Englander Bets on These 3 Penny Stocks
TipRanks · 06/10 14:35
Edited Transcript of AGRX earnings conference call or presentation 5-May-20 8:30pm GMT
Thomson Reuters StreetEvents · 05/28 06:06

Industry

Pharmaceuticals
+1.00%
Pharmaceuticals & Medical Research
+1.21%

Hot Stocks

Symbol
Price
%Change

About AGRX

Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company's lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.
More

Webull offers kinds of Agile Therapeutics Inc stock information, including NASDAQ:AGRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGRX stock methods without spending real money on the virtual paper trading platform.